Related Experiment Video
Updated: Nov 11, 2025
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
MAFLD considerations as a part of the global hepatitis C elimination effort: an international perspective
Yasser Fouad1, Jeffrey V Lazarus2,3, Francesco Negro3
1Minia, Egypt.
Background:
The World Health Organization (WHO) set a goal to eliminate hepatitis C (HCV) infection globally by 2030, with specific targets to reduce new viral hepatitis infections by 80% and reduce related deaths by 65%. However, an overlooked aspect that may hinder these efforts is the impact other liver diseases could have by continuing to drive liver disease progression and offset the beneficial impact of DAAs on end-stage liver disease and hepatocellular carcinoma (HCC). In particular, the decrease in HCV prevalence has been countered by a marked increase in the prevalence of metabolic-associated fatty liver disease (MAFLD).
Aims:
To review the potential interaction of HCV and MAFLD.
Methods:
We have reviewed the literature relating to an arrange of interaction of HCV, metabolic dysfunction and MAFLD.
Results:
In this viewpoint, international experts suggest a holistic and multidisciplinary approach for the management of the growing number of treated HCV patients who achieved SVR, taking into consideration the overlooked impact of MAFLD for reducing morbidity and mortality in people who have had HCV.
Conclusions:
This will strengthen and improve the continuum of care cascade for patients with liver disease(s) and holds the potential to alleviate the cost burden of disease; and increase quality of life for patients following DAAs treatment.
Insights
Metabolic-associated fatty liver disease (MAFLD) is increasingly impacting patients successfully treated for hepatitis C (HCV). Addressing MAFLD alongside HCV is crucial for reducing liver disease progression and improving patient outcomes post-treatment.
Area of Science:
- Hepatology
- Viral Hepatitis
- Metabolic Liver Disease
Background:
- The World Health Organization aims to eliminate hepatitis C (HCV) by 2030.
- Increased metabolic-associated fatty liver disease (MAFLD) prevalence may offset gains from HCV treatment.
- Co-existing liver diseases can drive progression and hinder HCV elimination goals.
Purpose of the Study:
- To review the interactions between HCV and MAFLD.
- To highlight the impact of MAFLD on patients treated for HCV.
Main Methods:
- Literature review on HCV, metabolic dysfunction, and MAFLD.
- Expert viewpoint on managing co-existing liver conditions.
Main Results:
- HCV treatment success (SVR) is challenged by rising MAFLD.
- International experts recommend a holistic approach for treated HCV patients.
- MAFLD's impact on morbidity and mortality in HCV patients is significant.
Conclusions:
- A multidisciplinary approach is needed for patients with a history of HCV and MAFLD.
- Integrating MAFLD management improves the continuum of care for liver disease patients.
- Addressing MAFLD can reduce disease burden and enhance quality of life after HCV treatment.
More Related Videos
Related Concept Videos
01:26Standard Precaution
Hand hygiene is the most crucial means to prevent the transmission of disease. Employers are legally required to provide their workers with personal protective equipment (PPE) to minimize exposure or contact with...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
01:26Methods Of Healthcare Delivery System
Managed Care System:
The managed care system is designed to control the cost while maintaining the quality of care. The patient's care from admission to discharge is planned by the primary care provider or the case manager, also known as the gatekeeper. In a managed care system, the number of care providers is...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
01:22Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
01:28International Nursing Organizations II
The WHO provides expert team support, including funding, vaccines, testing, and treatment tools at the country level to fight...